Novacyt Total Liabilities
Novacyt total liabilities. Based on the latest financial reports, Novacyt (ALNOV) has total liabilities worth €16.94 Million EUR (≈ $19.81 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Novacyt to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Novacyt (2008–2025)
Total liabilities of Novacyt from 2008 to 2025. This chart illustrates how Novacyt's total liabilities have evolved over time, based on quarterly financial data. Explore ALNOV long-term investments to assets to see how much of total assets are deployed in long-term investments.
Novacyt Competitors by Total Liabilities
The table below lists competitors of Novacyt ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Globe Metals & Mining Ltd
AU:GBE
|
Australia | AU$628.00K |
|
Yao I Fabric Co Ltd
TWO:4430
|
Taiwan | NT$1.82 Billion |
|
Mudajaya Group Bhd
KLSE:5085
|
Malaysia | RM1.14 Billion |
|
Vroom, Inc. Common Stock
NASDAQ:VRM
|
USA | $820.33 Million |
|
Ocumetics Technology Corp
V:OTC
|
Canada | CA$6.24 Million |
|
Radiant Cash Management Services Limited
NSE:RADIANTCMS
|
India | Rs-2.75 Billion |
|
Indo Acidatama Tbk
JK:SRSN
|
Indonesia | Rp379.93 Billion |
|
AS Ekspress Grupp
F:DYC
|
Germany | €59.17 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Novacyt's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Novacyt's balance sheet.
Liquidity & Leverage Metrics
Novacyt Total Liabilities Ratios Explained
Novacyt total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novacyt's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novacyt (2008–2025)
The table below shows the annual total liabilities of Novacyt from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €16.94 Million ≈ $19.81 Million |
-25.54% |
| 2024-12-31 | €22.75 Million ≈ $26.60 Million |
-51.15% |
| 2023-12-31 | €46.57 Million ≈ $54.45 Million |
+81.32% |
| 2022-12-31 | €25.68 Million ≈ $30.03 Million |
-38.67% |
| 2021-12-31 | €41.88 Million ≈ $48.96 Million |
-49.88% |
| 2020-12-31 | €83.57 Million ≈ $97.70 Million |
+493.86% |
| 2019-12-31 | €14.07 Million ≈ $16.45 Million |
+26.14% |
| 2018-12-31 | €11.16 Million ≈ $13.04 Million |
+37.94% |
| 2017-12-31 | €8.09 Million ≈ $9.45 Million |
-25.14% |
| 2016-12-31 | €10.80 Million ≈ $12.63 Million |
+64.34% |
| 2015-12-31 | €6.57 Million ≈ $7.69 Million |
+3.13% |
| 2014-12-31 | €6.37 Million ≈ $7.45 Million |
+639.23% |
| 2013-12-31 | €862.25K ≈ $1.01 Million |
-55.98% |
| 2012-12-31 | €1.96 Million ≈ $2.29 Million |
-2.26% |
| 2011-12-31 | €2.00 Million ≈ $2.34 Million |
-27.00% |
| 2010-12-31 | €2.75 Million ≈ $3.21 Million |
+6.82% |
| 2009-12-31 | €2.57 Million ≈ $3.00 Million |
+34.56% |
| 2008-12-31 | €1.91 Million ≈ $2.23 Million |
-- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more